Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

IRON

Disc Medicine Inc

Mar 12 • 04:00PM ET

53.93

Dollar change +0.04
Percentage change 0.07	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX ALNY CRSP BEAM EDIT NTLA SRPT IONS BLUE SGMO

| Held by: VTI IWM VXF XBI IWN SCHA IBB VTWO VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-3.99	Insider Own	38.61%	Shs Outstand	29.87M	Perf Week	-5.25%
Market Cap	1.86B	Forward P/E	-	EPS next Y	-5.22	Insider Trans	-0.83%	Shs Float	21.22M	Perf Month	-1.43%
Income	-109.36M	PEG	-	EPS next Q	-1.14	Inst Own	51.71%	Short Float	10.94%	Perf Quarter	-16.80%
Sales	0.00M	P/S	-	EPS this Y	-22.73%	Inst Trans	-3.66%	Short Ratio	6.63	Perf Half Y	4.23%
Book/sh	14.85	P/B	3.63	EPS next Y	-7.33%	ROA	-25.29%	Short Interest	2.32M	Perf Year	-17.40%
Cash/sh	14.17	P/C	3.81	EPS next 5Y	-2.60%	ROE	-27.73%	52W Range	25.60 - 68.86	Perf YTD	-14.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	38.12%	ROI	-23.10%	52W High	-21.68%	Beta	0.72
Dividend TTM	-	Quick Ratio	21.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	110.66%	ATR (14)	2.45
Dividend Ex-Date	-	Current Ratio	21.17	EPS Y/Y TTM	-14.19%	Oper. Margin	-	RSI (14)	44.02	Volatility	4.92% 4.15%
Employees	84	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	94.82
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-1.90%	Payout	-	Rel Volume	1.54	Prev Close	53.89
Sales Surprise	-	EPS Surprise	13.31%	Sales Q/Q	-	Earnings	Feb 27 BMO	Avg Volume	350.28K	Price	53.93
SMA20	-1.23%	SMA50	-5.23%	SMA200	4.18%	Trades		Volume	539,617	Change	0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-25	Initiated	TD Cowen	Buy
Nov-05-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$85
Nov-04-24	Upgrade	Raymond James	Outperform → Strong Buy	$66 → $110
Oct-23-24	Initiated	Jefferies	Buy	$89
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight	$75
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform	$40
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $65
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy	$50 → $75
Jun-07-23	Initiated	H.C. Wainwright	Buy	$55
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

Show Previous Ratings

Mar-03-25 09:55AM	Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know (Zacks)
Feb-27-25 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-25 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-25 09:55AM	Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-23-25 08:28AM	Disc raises $225.5m as it eyes approval of rare skin disorder drug (Pharmaceutical Technology)
09:35PM	Loading…
Jan-22-25 09:35PM	Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-21-25 04:01PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
07:45AM	Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission (GlobeNewswire)
Jan-20-25 07:00PM	Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Jan-17-25 04:00PM	Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-10-25 09:00AM	Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 (GlobeNewswire) -5.27%
Dec-09-24 12:00PM	Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-24 08:00PM	Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-24 06:10AM	Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-13-24 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Nov-12-24 08:00AM	Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 10:38AM	Disc Medicine secures $200m financing to support trials (Clinical Trials Arena)
Nov-08-24 08:30AM	Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. (GlobeNewswire)
Nov-05-24 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +11.20%
Nov-04-24 01:44PM	Disc teases potential NDA for rare skin disorder drug (Pharmaceutical Technology) +23.59%
07:50AM	Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval (GlobeNewswire)
Nov-01-24 04:01PM	Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire) +5.15%
Oct-25-24 01:00PM	Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-23-24 08:00AM	Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer (GlobeNewswire) -7.72%
Oct-11-24 08:00AM	Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Sep-19-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffe, MD as Chief Regulatory Officer (GlobeNewswire)
08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caff , MD as Chief Regulatory Officer (GlobeNewswire)
Aug-30-24 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-28-24 08:11PM	Bitfarms Technologies, Vestis, and More Stocks See Action From Activist Investors (Barrons.com)
08:03AM	Loading…
Jun-14-24 08:03AM	Disc Medicine Announces Underwritten Offering of Common Stock (GlobeNewswire) +18.16%
07:30AM	Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-30-24 09:00AM	Disc Medicine to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-13-24 08:00AM	Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-11-24 05:31AM	Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:54PM	IRON Stock Earnings: Disc Medicine Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-02-24 02:24PM	Disc Medicine (IRON) Down on Mixed Results From AURORA Study (Zacks) -6.36%
Apr-01-24 04:19PM	Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study (Investor's Business Daily) -45.05%
08:00AM	Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-23-24 05:31AM	Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance (GuruFocus.com)
Mar-21-24 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
Mar-06-24 04:30PM	Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire) -5.18%
Feb-26-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer (GlobeNewswire)
Feb-20-24 08:30AM	Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease (GlobeNewswire)
Feb-09-24 09:00AM	Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera (GlobeNewswire)
Feb-07-24 08:00AM	Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer (GlobeNewswire)
Jan-03-24 05:00PM	Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:30PM	Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board (GlobeNewswire)
Dec-15-23 03:01PM	Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON) (GuruFocus.com)
Dec-11-23 08:30PM	Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
12:00PM	Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-23 07:06AM	Insider Sell Alert: CFO Joanne Bryce Sells 2,541 Shares of Disc Medicine Inc (IRON) (GuruFocus.com) +5.98%
Nov-14-23 04:44PM	Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin (GlobeNewswire)
Nov-13-23 09:55AM	How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17% (Zacks)
Nov-09-23 09:34AM	Disc Medicine Inc (IRON) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
08:30AM	Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates (GlobeNewswire)
Oct-23-23 09:15AM	Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce (GlobeNewswire)
Oct-03-23 08:30AM	Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers (GlobeNewswire)
Sep-20-23 04:30PM	Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera (GlobeNewswire)
Aug-30-23 04:15PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 11:20AM	Stock Screen Finds These Growth Stocks Outperforming The S&P 500 (Investor's Business Daily)
Aug-11-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
08:00AM	Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 09:00AM	Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Jul-25-23 09:55AM	Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-22-23 04:15PM	Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-20-23 07:33PM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +7.20%
Jun-13-23 10:39PM	Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-12-23 04:00PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.92%
01:59AM	4 big analyst picks: Adobe a buy on AI hopes, says Wells Fargo (Investing.com)
Jun-09-23 04:13PM	Why Perfectly Rated Disc Medicine, With A 287% Move This Year, Just Put Up Another Big Gain (Investor's Business Daily) +15.76%
07:00AM	Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
Jun-01-23 03:10PM	Why Shares of Disc Medicine Opco Climbed This Week (Motley Fool) +7.06%
May-31-23 04:00PM	Disc Medicine to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +12.01%
May-15-23 07:00AM	Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-11-23 10:15AM	Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
May-10-23 10:23AM	Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season? (Zacks) +5.24%
May-05-23 08:50AM	Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
May-04-23 12:00PM	Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know (Zacks)
Apr-28-23 05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
Apr-21-23 08:30AM	Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +11.57%
Apr-19-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
Apr-13-23 11:00AM	Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-31-23 07:00AM	Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-30-23 07:05AM	Disc Medicine Opco Inc (NASDAQ:IRON) most popular amongst private equity firms who own 48% of the shares, institutions hold 21% (Simply Wall St.)
Mar-21-23 07:00AM	Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Feb-16-23 08:00AM	Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia (GlobeNewswire)
Feb-14-23 06:30AM	Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs (GlobeNewswire)
Feb-08-23 04:00PM	Disc Medicine to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 07:00AM	Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis (GlobeNewswire)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company was founded in October 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OrbiMed Genesis Master Fund, L	Director	Mar 10 '25	Proposed Sale	55.67	74,800	4,164,116		Mar 10 06:46 PM
OrbiMed Private Investments VI	Director	Mar 10 '25	Proposed Sale	55.67	193,400	10,766,578		Mar 10 06:45 PM
OrbiMed Private Investments VI	Director	Mar 10 '25	Proposed Sale	55.67	299,200	16,656,464		Mar 10 06:44 PM
Stephenson Pamela	Chief Commercial Officer	Feb 18 '25	Sale	54.58	3,137	171,217	69,529	Feb 20 07:38 PM
Khara Rahul	Chief Legal Officer	Feb 18 '25	Sale	54.58	1,161	63,367	37,583	Feb 20 07:36 PM
Savage William Jacob	Chief Medical Officer	Feb 18 '25	Sale	54.58	1,638	89,402	68,498	Feb 20 07:33 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Feb 18 '25	Sale	54.58	1,610	87,874	40,555	Feb 20 07:31 PM
Franchi Jean M.	Chief Financial Officer	Feb 18 '25	Sale	54.58	3,136	171,163	69,530	Feb 20 07:29 PM
Quisel John D	Chief Executive Officer	Feb 18 '25	Sale	54.58	5,574	304,229	154,828	Feb 20 07:27 PM
Savage William Jacob	Chief Medical Officer	Feb 03 '25	Option Exercise	2.65	5,731	15,187	46,136	Feb 12 06:33 PM
Atlas Venture Fund X, L.P.	Shareholder	Feb 05 '25	Proposed Sale	54.32	112,211	6,095,302		Feb 05 04:05 PM
Khara Rahul	Chief Legal Officer	Feb 03 '25	Option Exercise	14.69	7,500	110,175	21,535	Feb 04 05:18 PM
Khara Rahul	Chief Legal Officer	Feb 03 '25	Sale	55.54	7,500	416,574	14,035	Feb 04 05:18 PM
Atlas Venture Fund X, L.P.	Shareholder	Feb 04 '25	Proposed Sale	54.99	6,350	349,186		Feb 04 05:14 PM
Atlas Venture Fund X, L.P.	Shareholder	Feb 03 '25	Proposed Sale	55.80	6,439	359,296		Feb 03 04:28 PM
Khara Rahul	Chief Legal Officer	Jan 02 '25	Option Exercise	14.69	7,500	110,175	21,535	Jan 06 05:56 PM
Khara Rahul	Chief Legal Officer	Jan 02 '25	Sale	62.75	7,500	470,658	14,035	Jan 06 05:56 PM
Quisel John D	Chief Executive Officer	Dec 30 '24	Option Exercise	9.86	13,012	128,298	85,077	Jan 02 07:13 PM
Quisel John D	Chief Executive Officer	Dec 31 '24	Option Exercise	1.01	10,000	10,100	82,065	Jan 02 07:13 PM
Quisel John D	Chief Executive Officer	Dec 30 '24	Sale	61.95	13,012	806,058	72,065	Jan 02 07:13 PM
RAHUL KHARA	Officer	Jan 02 '25	Proposed Sale	63.40	15,000	951,000		Jan 02 04:20 PM
JOHN QUISEL	Director	Dec 30 '24	Proposed Sale	64.12	13,012	834,329		Dec 30 04:11 PM
Quisel John D	Chief Executive Officer	Dec 23 '24	Option Exercise	2.65	19,820	52,523	91,885	Dec 26 05:18 PM
Quisel John D	Chief Executive Officer	Dec 23 '24	Sale	63.14	19,820	1,251,357	72,065	Dec 26 05:18 PM
JOHN QUISEL	Director	Dec 23 '24	Proposed Sale	64.50	19,820	1,278,390		Dec 23 04:21 PM
Quisel John D	Chief Executive Officer	Dec 16 '24	Option Exercise	1.01	12,791	12,919	84,856	Dec 18 07:41 PM
Quisel John D	Chief Executive Officer	Dec 16 '24	Sale	66.01	12,791	844,314	72,065	Dec 18 07:41 PM
JOHN QUISEL	Director	Dec 16 '24	Proposed Sale	64.89	12,791	830,008		Dec 16 04:39 PM
White William Richard	Director	Dec 02 '24	Option Exercise	3.39	1,957	6,635	1,957	Dec 04 07:43 PM
White William Richard	Director	Dec 02 '24	Sale	64.63	1,957	126,490	0	Dec 04 07:43 PM
Savage William Jacob	Chief Medical Officer	Nov 25 '24	Option Exercise	12.15	14,183	172,313	54,588	Nov 26 08:03 PM
Savage William Jacob	Chief Medical Officer	Nov 25 '24	Sale	65.45	14,183	928,326	40,405	Nov 26 08:03 PM
WILLIAM SAVAGE	Officer	Nov 25 '24	Proposed Sale	64.96	14,183	921,328		Nov 25 04:46 PM
Savage William Jacob	Chief Medical Officer	Nov 15 '24	Option Exercise	9.86	9,158	90,298	49,563	Nov 19 06:46 PM
Savage William Jacob	Chief Medical Officer	Nov 15 '24	Sale	59.64	9,158	546,153	40,405	Nov 19 06:46 PM
WILLIAM SAVAGE	Officer	Nov 15 '24	Proposed Sale	60.67	9,158	555,616		Nov 15 04:39 PM
White William Richard	Director	Nov 04 '24	Option Exercise	45.69	7,136	326,044	7,136	Nov 05 07:16 PM
White William Richard	Director	Nov 01 '24	Option Exercise	9.86	201	1,982	201	Nov 05 07:16 PM
White William Richard	Director	Nov 04 '24	Sale	58.61	7,136	418,206	0	Nov 05 07:16 PM
White William Richard	Director	Nov 01 '24	Sale	46.37	201	9,319	0	Nov 05 07:16 PM
White William Richard	Director	Nov 04 '24	Proposed Sale	47.13	7,136	336,320		Nov 04 04:07 PM
White William Richard	Director	Nov 01 '24	Proposed Sale	44.82	2,158	96,722		Nov 01 04:19 PM
White William Richard	Director	Oct 01 '24	Option Exercise	9.86	201	1,982	201	Oct 03 04:29 PM
White William Richard	Director	Oct 01 '24	Sale	51.31	201	10,312	0	Oct 03 04:29 PM
Savage William Jacob	Chief Medical Officer	Sep 16 '24	Sale	47.41	1,500	71,115	40,405	Sep 18 04:05 PM
WILLIAM SAVAGE	Officer	Sep 16 '24	Proposed Sale	47.79	1,500	71,685		Sep 16 04:39 PM
White William Richard	Director	Sep 03 '24	Option Exercise	3.39	1,957	6,635	1,957	Sep 05 04:06 PM
White William Richard	Director	Sep 03 '24	Sale	49.65	1,957	97,158	0	Sep 05 04:06 PM
Savage William Jacob	Chief Medical Officer	Sep 03 '24	Sale	50.59	1,500	75,885	41,905	Sep 04 04:05 PM
WILLIAM SAVAGE	Officer	Sep 03 '24	Proposed Sale	50.82	1,500	76,230		Sep 03 04:15 PM
White William Richard	Director	Aug 01 '24	Option Exercise	9.86	201	1,982	201	Aug 05 04:15 PM
White William Richard	Director	Aug 01 '24	Sale	43.44	201	8,731	0	Aug 05 04:15 PM
White William Richard	Director	Aug 01 '24	Proposed Sale	43.16	9,696	418,479		Aug 01 05:10 PM
Quisel John D	Chief Executive Officer	Jul 08 '24	Option Exercise	1.01	3,000	3,030	72,065	Jul 10 04:15 PM
White William Richard	Director	Jul 01 '24	Option Exercise	9.86	201	1,982	201	Jul 03 04:15 PM
White William Richard	Director	Jul 01 '24	Sale	46.04	201	9,253	0	Jul 03 04:15 PM
Bitterman Kevin	Director	Jun 17 '24	Buy	36.00	222,223	8,000,028	420,549	Jun 20 08:00 PM
Ashiya Mona	Director	Jun 17 '24	Buy	36.00	83,334	3,000,024	941,569	Jun 20 05:27 PM
ORBIMED ADVISORS LLC	Director	Jun 17 '24	Buy	36.00	83,334	3,000,024	941,569	Jun 20 05:19 PM
White William Richard	Director	Jun 03 '24	Option Exercise	3.39	1,957	6,635	1,957	Jun 05 04:05 PM
White William Richard	Director	Jun 03 '24	Sale	36.08	1,957	70,608	0	Jun 05 04:05 PM
White William Richard	Director	May 01 '24	Option Exercise	9.86	201	1,982	201	May 03 04:05 PM
White William Richard	Director	May 01 '24	Sale	28.63	201	5,755	0	May 03 04:05 PM
White William Richard	Director	Apr 11 '24	Option Exercise	4.91	2,560	12,581	2,560	Apr 15 06:27 PM
White William Richard	Director	Apr 11 '24	Sale	31.80	2,560	81,407	0	Apr 15 06:27 PM
Savage William Jacob	Chief Medical Officer	Apr 10 '24	Option Exercise	2.65	21,870	57,956	43,405	Apr 11 05:02 PM

Open in Screener

REPL

Replimune Group Inc

Mar 12 • 04:00PM ET

12.11

Dollar change +0.67
Percentage change 5.86	%

Healthcare • Biotechnology • USA • NASD

REPL Replimune Group Inc daily Stock Chart

Peers: MRNA BNTX FATE SGMO KPTI ALVR PGEN ADAP ANIX ENTX

| Held by: VTI IWM VXF XBI IWN IBB VTWO SCHA VHT DFAS

Index	RUT	P/E	-	EPS (ttm)	-3.14	Insider Own	20.10%	Shs Outstand	77.01M	Perf Week	-1.46%
Market Cap	932.65M	Forward P/E	-	EPS next Y	-2.74	Insider Trans	-0.14%	Shs Float	61.53M	Perf Month	-7.70%
Income	-228.24M	PEG	-	EPS next Q	-0.75	Inst Own	88.74%	Short Float	14.86%	Perf Quarter	-7.42%
Sales	0.00M	P/S	-	EPS this Y	11.67%	Inst Trans	16.16%	Short Ratio	12.40	Perf Half Y	15.00%
Book/sh	6.26	P/B	1.93	EPS next Y	4.25%	ROA	-40.16%	Short Interest	9.14M	Perf Year	34.11%
Cash/sh	6.97	P/C	1.74	EPS next 5Y	13.91%	ROE	-50.50%	52W Range	4.92 - 17.00	Perf YTD	0.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.52%	ROI	-41.16%	52W High	-28.76%	Beta	1.19
Dividend TTM	-	Quick Ratio	11.43	Sales past 5Y	0.00%	Gross Margin	-	52W Low	146.14%	ATR (14)	0.88
Dividend Ex-Date	-	Current Ratio	11.43	EPS Y/Y TTM	4.28%	Oper. Margin	-	RSI (14)	44.53	Volatility	6.96% 7.09%
Employees	331	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	21.62
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	-3.59%	Payout	-	Rel Volume	0.92	Prev Close	11.44
Sales Surprise	-	EPS Surprise	-11.88%	Sales Q/Q	-	Earnings	Feb 12 BMO	Avg Volume	737.20K	Price	12.11
SMA20	-6.23%	SMA50	-4.77%	SMA200	9.61%	Trades		Volume	678,084	Change	5.86%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	ROTH MKM	Buy	$17
Apr-17-23	Resumed	Piper Sandler	Overweight	$44
Nov-19-21	Initiated	Piper Sandler	Overweight	$52
Oct-15-21	Resumed	BTIG Research	Buy	$60
Nov-17-20	Initiated	BTIG Research	Buy	$60
Nov-02-20	Initiated	Jefferies	Buy	$67
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy	$25 → $54
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral	$25
May-05-20	Initiated	Barclays	Overweight	$21
Sep-04-19	Initiated	ROTH Capital	Buy	$20
Jul-23-19	Initiated	Chardan Capital Markets	Buy	$28
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight	$27 → $26
Jul-08-19	Initiated	H.C. Wainwright	Buy	$26
Apr-25-19	Initiated	Wedbush	Outperform	$24
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	Leerink Partners	Outperform	$25
Aug-14-18	Initiated	JP Morgan	Overweight	$26

Show Previous Ratings

Mar-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-25 08:00AM	Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.32%
Feb-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.88%
Jan-23-25 07:06AM	Replimune price target raised to $21 from $17 at H.C. Wainwright (TipRanks) +5.61%
Jan-21-25 01:01PM	Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy (GuruFocus.com) +16.86%
08:00AM	Loading…
08:00AM	Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Jan-10-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-25 08:00AM	Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials (GlobeNewswire)
Dec-23-24 08:00AM	Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-24 11:55PM	Replimune Announces Pricing of Upsized Public Offering (GlobeNewswire) -11.19% +8.45%
07:09AM	Replimune Announces Proposed Public Offering (GlobeNewswire)
Nov-22-24 04:00PM	S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results (Benzinga) +35.11%
05:48AM	Replimune's stock surges 19% after-hours on FDA BLA submission (Investing.com)
Nov-21-24 04:05PM	Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway (GlobeNewswire)
Nov-12-24 08:00AM	Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
01:00PM	Loading…
Nov-09-24 01:00PM	Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) (GlobeNewswire)
Nov-08-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-24 09:15AM	Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Oct-09-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
Oct-07-24 09:11PM	Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings (GuruFocus.com)
Oct-01-24 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.58%
Sep-15-24 09:45AM	Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-09-24 08:00AM	Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 (GlobeNewswire)
Sep-05-24 08:00AM	Stockholders Vote to Elect Madhavan Balachandran to Board of Directors (GlobeNewswire)
Aug-22-24 08:00AM	Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-14-24 04:33PM	Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy (Pharmaceutical Technology)
Aug-13-24 08:00AM	Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma (GlobeNewswire)
Aug-08-24 08:00AM	Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-24 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jun-13-24 08:30AM	Replimune Announces $100 Million Private Placement Financing (GlobeNewswire) +7.26%
09:03AM	Loading…
Jun-07-24 09:03AM	Replimune (REPL) Gains on Positive Data From Melanoma Study (Zacks) +11.11%
08:00AM	Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-06-24 12:16PM	Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? (Benzinga) +27.88%
07:00AM	Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma (GlobeNewswire)
Jun-03-24 08:00AM	Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-24 05:00PM	Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.77%
May-16-24 01:53PM	REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 (InvestorPlace)
08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-07-24 05:00PM	Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-24 07:30AM	Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions (GlobeNewswire)
Mar-11-24 09:55AM	How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17% (Zacks)
Mar-08-24 12:00PM	What Makes Replimune Group, Inc. (REPL) a New Buy Stock (Zacks)
Mar-06-24 08:00AM	Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Replimune to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-23-24 09:55AM	Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High? (Zacks)
Feb-08-24 08:42AM	Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway (GuruFocus.com)
08:00AM	Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-16-24 03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire) -5.55%
Dec-28-23 08:00AM	Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 07:32AM	UPDATE 1-Replimune's skin cancer drug fails in mid-stage study (Reuters) -45.21%
07:10AM	CORRECTED-Replimune's skin cancer drug fails in mid-stage study (Reuters)
07:00AM	Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire)
Nov-08-23 09:10AM	Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research (GlobeNewswire) +6.56%
Nov-07-23 08:00AM	Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -15.85%
Nov-03-23 07:30PM	Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -9.37%
Oct-17-23 03:00AM	Tessellate BIO Emerges from Stealth (GlobeNewswire)
Sep-19-23 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.79%
08:00AM	Replimune Announces Appointment of Emily Hill as Chief Financial Officer (GlobeNewswire)
Sep-14-23 01:23PM	Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc (GuruFocus.com)
Aug-03-23 08:00AM	Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.69%
Aug-01-23 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 04:01PM	Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma (Business Wire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-20-23 08:00AM	Replimune Announces Sander Slootweg will Depart from its Board of Directors (GlobeNewswire) -5.44%
Jun-06-23 10:00AM	Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting (GlobeNewswire)
Jun-05-23 08:00AM	Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors (GlobeNewswire) +19.01%
Jun-03-23 02:15PM	Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-01-23 04:01PM	Replimune to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-25-23 05:00PM	Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-18-23 08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-17-23 10:02AM	Is a Surprise Coming for Replimune (REPL) This Earnings Season? (Zacks) +5.46%
May-09-23 08:00AM	Replimune to Participate in the Piper Sandler Spring Biopharma Symposium (GlobeNewswire)
Mar-31-23 09:35AM	Down -22% in 4 Weeks, Here's Why Replimune Group, Inc. (REPL) Looks Ripe for a Turnaround (Zacks)
Mar-08-23 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 09:35AM	Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.29%
Feb-09-23 08:50AM	Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) -9.12%
08:00AM	Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-23 08:00AM	Replimune to Present at the Virtual SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-06-23 09:55AM	Wall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a Bet (Zacks)
09:04AM	Institutional investors may adopt severe steps after Replimune Group, Inc.'s (NASDAQ:REPL) latest 5.3% drop adds to a year losses (Simply Wall St.)
08:50AM	Recent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's Why (Zacks)
Jan-05-23 05:44AM	The Petri Dish: Fulcrum CEO steps down; Moderna cools on mpox vaccine (American City Business Journals)
Jan-04-23 08:05AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer (GlobeNewswire)
Jan-03-23 08:00AM	Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 10:46AM	Replimune Breaks Out: Could Rise 30% From Here (TheStreet.com) +5.76%
Dec-12-22 02:36PM	Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform (Benzinga)
Dec-08-22 09:04PM	Replimune Announces Pricing of Public Offering (GlobeNewswire)
Dec-07-22 04:04PM	Replimune Announces Proposed Public Offering (GlobeNewswire) +22.23%
10:05AM	Replimune Shares Surge After Early Data From Pretreated Melanoma Patients (Benzinga)
07:00AM	Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update (GlobeNewswire)
06:30AM	Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma (GlobeNewswire)
Nov-23-22 08:00AM	Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-22-22 08:00AM	Replimune to Host Virtual Investor Event on December 7, 2022 (GlobeNewswire) +5.14%
Nov-03-22 08:00AM	Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sushil	Chief Executive Officer	Dec 16 '24	Sale	12.42	10,000	124,200	202,014	Dec 18 09:00 PM
Sushil Patel	Chief Strategy Officer	Dec 16 '24	Proposed Sale	12.57	15,000	188,550		Dec 16 04:48 PM
Xynos Konstantinos	Chief Medical Officer	Nov 18 '24	Sale	10.78	7,246	78,112	109,885	Nov 20 09:31 PM
Sarchi Christopher	Chief Commercial Officer	Nov 18 '24	Sale	10.78	5,207	56,131	87,045	Nov 20 09:30 PM
Hill Emily Luisa	Chief Financial Officer	Aug 16 '24	Sale	10.18	8,938	90,989	101,057	Aug 19 08:00 PM
Xynos Konstantinos	Chief Medical Officer	Jun 07 '24	Sale	7.50	15,881	119,108	117,131	Jun 10 08:30 PM
Sarchi Christopher	Chief Commercial Officer	May 16 '24	Sale	6.47	2,218	14,350	92,252	May 20 08:06 PM
Schwendenman Andrew	Chief Accounting Officer	May 16 '24	Sale	6.47	2,298	14,868	38,238	May 20 08:06 PM
Love Colin	Chief Operating Officer	May 16 '24	Sale	6.47	17,615	113,969	777,345	May 20 08:05 PM
Astley-Sparke Philip	Executive Chairman	May 16 '24	Sale	6.47	37,928	245,394	1,487,350	May 20 08:04 PM
Coffin Robert	Director	May 16 '24	Sale	6.47	11,464	74,172	1,821,872	May 20 08:02 PM
Patel Sushil	Chief Executive Officer	May 16 '24	Sale	6.47	20,194	130,655	212,014	May 20 08:01 PM
Xynos Konstantinos	Chief Medical Officer	May 16 '24	Sale	6.47	6,367	41,194	133,012	May 20 08:00 PM

IRON

Disc Medicine Inc

REPL

Replimune Group Inc

Upgrade your FINVIZ experience